ASH 2018 Annual Meeting Highlights in Hodgkin Lymphoma

Combination of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with RR HL – Catherine Diefenbach, MD Begin

Nivolumab for RR cHL after Autologous Hematopoietic Cell Transplantation – Andreas Engert, MD Begin

Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group – Andreas Engert, MD Begin

Results of a Phase II Intergroup Trial on B-CAP in Older Patients with Advanced-Stage HL – Andreas Engert, MD Begin

Detailed Analysis from the Phase 3 ECHELON-1 Study of Older Patients with Previously Untreated cHL – Andrew M. Evens, DO, MSc, FACP Begin

Response-Adapted Therapy for Stage III/IV HL Demonstrates Limitation of PET-Adapted Approach – Andrew M. Evens, DO, MSc, FACP Begin

Brentuximab Vedotin in Combination with Nivolumab or Chemotherapy in R/R Patients or AYA Patients – Julie M. Vose, MD, MBA Begin